Advances in the genetic assessment of tumor-driving oncogenes allow for a categorization of BRAF mutants into three classes based upon their kinase activity, ability to signal as monomers or dimers, and dependency on RAS signaling [14••]. This evidence concerns the gene BRAF and neoplasm.